Skip to main content
. 2020 May 24;20:364. doi: 10.1186/s12879-020-05057-9

Table 1.

Demographics and outcomes (n = 103 subjects)

Median age (range) y.o. 35 (1–75)
Male: female 69: 34
Distribution of cases in age groupa, N(%)
 1 - ≤5 years 2/153 (1.3%)
 6 - ≤18 years 19/190 (10%)
 19 - ≤45 years 53/378 (14%)
 > 45 years 29/254 (11.4%)
Day of onset (median, range), days 5 (1–12)
Length of stay (median, range), days 6 (1–36)
Antibiotics use from 90 subjects with documented history, N (%) 76 (84%)
 Ceftriaxone 17 (22.4%)
 Ciprofloxacin 9 (11.8%)
 Levofloxacin 9 (11.8%)
 Cefixime 2 (2.6%)
 Cefotaxime, Amoxicillin, Ampicillin, Cefadroxil, Meropenem, Chloramphenicol, Cefoperazone, Sulbactam, Cotrimoxazole 1 (1.3%), each
 Combination 2–3 antibiotics 30 (39.5%)
Outcomes, N (%)
 Recovered 72 (69.9%)
 Recovered with sequelaeb 24 (23.3%)
 Died 7 (6.8%)
By sitesa, N (%)
 Bandung 22/189 (11.6%)
 Denpasar 16/101 (15.8%)
 Jakarta 7/87 (8%)
 Makassar 5/131 (3.8%)
 Semarang 21/191 (10.9%)
 Surabaya 26/156 (16.7%)
 Yogyakarta 6/120 (5%)

afrom 975 subjects tested for Rickettsia typhi

bLethargy, arthralgia, anorexia, headache, dizziness, cough